FI953725A - Ornitiiniaminotransferaasi-inhibiittorien käyttö lääkeaineen valmistamiseksi Alzheimerin taudin hoitamiseksi - Google Patents

Ornitiiniaminotransferaasi-inhibiittorien käyttö lääkeaineen valmistamiseksi Alzheimerin taudin hoitamiseksi Download PDF

Info

Publication number
FI953725A
FI953725A FI953725A FI953725A FI953725A FI 953725 A FI953725 A FI 953725A FI 953725 A FI953725 A FI 953725A FI 953725 A FI953725 A FI 953725A FI 953725 A FI953725 A FI 953725A
Authority
FI
Finland
Prior art keywords
alzheimer
medicament
disease
manufacture
treatment
Prior art date
Application number
FI953725A
Other languages
English (en)
Swedish (sv)
Other versions
FI953725A0 (fi
Inventor
Nikolaus Seiler
Jean-Bernard Ducep
Karin Camille Jund
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of FI953725A publication Critical patent/FI953725A/fi
Publication of FI953725A0 publication Critical patent/FI953725A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
FI953725A 1993-02-05 1995-08-04 Ornitiiniaminotransferaasi-inhibiittorien käyttö lääkeaineen valmistamiseksi Alzheimerin taudin hoitamiseksi FI953725A0 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP93400303A EP0609630A1 (en) 1993-02-05 1993-02-05 Use of inhibitors of ornithine aminotransferase for the manufacture of a medicament for the treatment of Alzheimer's disease
PCT/US1993/011283 WO1994017795A1 (en) 1993-02-05 1993-11-19 Use of inhibitors of ornithine aminotransferase for the manufacture of a medicament for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
FI953725A true FI953725A (fi) 1995-08-04
FI953725A0 FI953725A0 (fi) 1995-08-04

Family

ID=8214677

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953725A FI953725A0 (fi) 1993-02-05 1995-08-04 Ornitiiniaminotransferaasi-inhibiittorien käyttö lääkeaineen valmistamiseksi Alzheimerin taudin hoitamiseksi

Country Status (14)

Country Link
US (1) US5637768A (fi)
EP (2) EP0609630A1 (fi)
JP (1) JPH08506577A (fi)
AU (1) AU682330B2 (fi)
CA (1) CA2152796A1 (fi)
FI (1) FI953725A0 (fi)
HU (1) HUT73173A (fi)
IL (1) IL107737A (fi)
MX (1) MX9400911A (fi)
NO (1) NO953072L (fi)
NZ (2) NZ280983A (fi)
TW (1) TW383337B (fi)
WO (1) WO1994017795A1 (fi)
ZA (1) ZA938836B (fi)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043616A2 (en) * 2001-11-16 2003-05-30 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
US7273888B2 (en) * 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
CN111362828A (zh) * 2020-03-30 2020-07-03 山西医科大学 一种18f标记的氟丙酰化鸟氨酸及其制备方法和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2041815T3 (es) * 1988-02-05 1993-12-01 Merrell Dow Pharmaceuticals Inc. Un procedimiento para la obtencion de derivados de ornitina 5-sustituidos.

Also Published As

Publication number Publication date
CA2152796A1 (en) 1994-08-18
MX9400911A (es) 1994-08-31
JPH08506577A (ja) 1996-07-16
NZ280983A (en) 1997-07-27
IL107737A (en) 1998-12-27
AU5614394A (en) 1994-08-29
EP0609630A1 (en) 1994-08-10
HUT73173A (en) 1996-06-28
TW383337B (en) 2000-03-01
WO1994017795A1 (en) 1994-08-18
FI953725A0 (fi) 1995-08-04
NO953072D0 (no) 1995-08-04
IL107737A0 (en) 1994-02-27
US5637768A (en) 1997-06-10
AU682330B2 (en) 1997-10-02
EP0682515A1 (en) 1995-11-22
NO953072L (no) 1995-08-04
ZA938836B (en) 1994-08-02
NZ258461A (en) 1997-03-24
HU9502320D0 (en) 1996-05-28

Similar Documents

Publication Publication Date Title
EP0735870A4 (en) USE OF PHOSPHOLIPASE-A2 INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
NO981911D0 (no) Anvendelse av rhodaninderivater for fremstilling av et medikament for behandling av Alzheimer's sykdom
IT9022471A0 (it) Procedimento e apparecchiatura per l'abbinamento univoco di farmaci corrispondenti a una terapia pescritta a un determinato paziente
NO306850B1 (no) Anvendelse av 5-halo-2-pyrimidinon-deoksyribose eller 5-halo-2-pyrimidinon for fremstilling av et medikament for behandling av leversykdom
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
HUP9903906A3 (en) Use of chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
FI962685A0 (fi) 2,3-diaryyli-1-bentsopyraanijohdannaisten käyttö lääkkeen valmistamiseksi luukadon ja osteoporoosin hoitamiseksi ja estämiseksi
IL117695A0 (en) Pharmaceutical agents for the treatment of alzheimer's disease
FI953725A (fi) Ornitiiniaminotransferaasi-inhibiittorien käyttö lääkeaineen valmistamiseksi Alzheimerin taudin hoitamiseksi
LV12067A (lv) 17B-N-vienaizvietota-karbamoil-4-aza-5alfa-androst-1-en-3-onu pielietojums medikamenta razosanai
DK0642338T3 (da) Anvendelse af (E)-2-(p-fluorphenethyl)-3-fluorallylamin i behandlingen af Alzheimers sygdom
NO307126B1 (no) Anvendelse av biologisk aktive ureidoderivater for fremstilling av et medikament for bruk i behandlingen av lentivirusindusert sykdom
DE551180T1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
NO960347L (no) Anvendelse av benzydamid ved behandling av patologiske tilstander forårsaket av TNF
AU8195091A (en) Ropinirole and domperidone for use in the manufacture of a medicament for the treatment of parkinson's disease
ZA947262B (en) Use of transdermal device containing (e)-2-(p-fluorophenethyl)-3-fluoroallylamine and its use for the treatment of alzheimer's disease
FI951041A (fi) (S)-(-)-alfa-etyyli-2-okso-1-pyrrolidiiniasetamidin käyttö valmistettaessa farmaseuttinen valmiste ahdistuksen hoitoon
KR940022019U (ko) 남성물리치료기
SI0664121T1 (en) Use of raloxifene and its analogs for the manufacture of a medicament for the treatment of atherosclerose and ischaemic heart disease
LV5177A3 (lv) Preparats "eridons" govju endometritu profilaksei un arstesanai
SE9300795D0 (sv) Ny princip foer smaertbehandling
ITTO920656A0 (it) Sedia per operativita' chirurgica
LV5179A3 (lv) Preparats "etoksidins" teju kunga un zarnu slimibu profilaksei un arstesanai
KR950000466U (ko) 남성물리치료기
SI1007040T1 (en) Use of phanquinone for the treatment of alzheimer's disease